vs
渤健（BIIB）与道明尼能源（D）财务数据对比。点击上方公司名可切换其他公司
道明尼能源的季度营收约是渤健的1.7倍（$4.2B vs $2.5B），道明尼能源净利率更高（13.9% vs 12.9%，领先1.0%），道明尼能源同比增速更快（23.2% vs 2.0%），过去两年道明尼能源的营收复合增速更高（9.3% vs 0.3%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
道明尼能源是总部位于美国弗吉尼亚州里士满的能源企业，为弗吉尼亚、北卡罗来纳、南卡罗来纳三州的部分地区供电，同时向犹他、爱达荷、怀俄明、西弗吉尼亚、俄亥俄、宾夕法尼亚、佐治亚等州的部分区域供应天然气，在印第安纳、伊利诺伊、康涅狄格、罗得岛也设有发电设施。
BIIB vs D — 直观对比
营收规模更大
D
是对方的1.7倍
$2.5B
营收增速更快
D
高出21.2%
2.0%
净利率更高
D
高出1.0%
12.9%
两年增速更快
D
近两年复合增速
0.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.5B | $4.2B |
| 净利润 | $319.5M | $586.0M |
| 毛利率 | — | — |
| 营业利润率 | — | 18.0% |
| 净利率 | 12.9% | 13.9% |
| 营收同比 | 2.0% | 23.2% |
| 净利润同比 | 32.8% | 871.1% |
| 每股收益（稀释后） | $2.15 | $0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBD
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.3B | $4.2B | ||
| Q3 25 | $2.5B | $4.5B | ||
| Q2 25 | $2.6B | $3.7B | ||
| Q1 25 | $2.4B | $4.1B | ||
| Q4 24 | $2.5B | $3.4B | ||
| Q3 24 | $2.5B | $3.8B | ||
| Q2 24 | $2.5B | $3.5B |
净利润BIIBD
| Q1 26 | $319.5M | — | ||
| Q4 25 | $-48.9M | $586.0M | ||
| Q3 25 | $466.5M | $1.0B | ||
| Q2 25 | $634.8M | $760.0M | ||
| Q1 25 | $240.5M | $646.0M | ||
| Q4 24 | $266.7M | $-76.0M | ||
| Q3 24 | $388.5M | $954.0M | ||
| Q2 24 | $583.6M | $572.0M |
毛利率BIIBD
| Q1 26 | — | — | ||
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — |
营业利润率BIIBD
| Q1 26 | — | — | ||
| Q4 25 | -2.5% | 18.0% | ||
| Q3 25 | 22.0% | 29.7% | ||
| Q2 25 | 28.1% | 29.5% | ||
| Q1 25 | 12.8% | 29.9% | ||
| Q4 24 | 11.9% | 11.4% | ||
| Q3 24 | 18.3% | 32.2% | ||
| Q2 24 | 28.3% | 23.3% |
净利率BIIBD
| Q1 26 | 12.9% | — | ||
| Q4 25 | -2.1% | 13.9% | ||
| Q3 25 | 18.4% | 22.3% | ||
| Q2 25 | 24.0% | 20.4% | ||
| Q1 25 | 9.9% | 15.8% | ||
| Q4 24 | 10.9% | -2.2% | ||
| Q3 24 | 15.8% | 25.2% | ||
| Q2 24 | 23.7% | 16.6% |
每股收益（稀释后）BIIBD
| Q1 26 | $2.15 | — | ||
| Q4 25 | $-0.35 | $0.66 | ||
| Q3 25 | $3.17 | $1.16 | ||
| Q2 25 | $4.33 | $0.88 | ||
| Q1 25 | $1.64 | $0.75 | ||
| Q4 24 | $1.82 | $-0.11 | ||
| Q3 24 | $2.66 | $1.12 | ||
| Q2 24 | $4.00 | $0.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.4B | $250.0M |
| 总债务越低越好 | — | $44.1B |
| 股东权益账面价值 | $18.7B | $29.1B |
| 总资产 | $29.5B | $115.9B |
| 负债/权益比越低杠杆越低 | — | 1.52× |
8季度趋势，按日历期对齐
现金及短期投资BIIBD
| Q1 26 | $3.4B | — | ||
| Q4 25 | — | $250.0M | ||
| Q3 25 | — | $932.0M | ||
| Q2 25 | — | $344.0M | ||
| Q1 25 | — | $355.0M | ||
| Q4 24 | — | $310.0M | ||
| Q3 24 | — | $1.8B | ||
| Q2 24 | — | $139.0M |
总债务BIIBD
| Q1 26 | — | — | ||
| Q4 25 | $6.3B | $44.1B | ||
| Q3 25 | $6.3B | $43.3B | ||
| Q2 25 | $6.3B | $40.3B | ||
| Q1 25 | $4.5B | $39.9B | ||
| Q4 24 | $6.3B | $37.5B | ||
| Q3 24 | $4.5B | $37.1B | ||
| Q2 24 | $6.3B | $36.6B |
股东权益BIIBD
| Q1 26 | $18.7B | — | ||
| Q4 25 | $18.3B | $29.1B | ||
| Q3 25 | $18.2B | $27.7B | ||
| Q2 25 | $17.6B | $27.2B | ||
| Q1 25 | $17.0B | $27.4B | ||
| Q4 24 | $16.7B | $27.3B | ||
| Q3 24 | $16.4B | $27.5B | ||
| Q2 24 | $15.9B | $27.1B |
总资产BIIBD
| Q1 26 | $29.5B | — | ||
| Q4 25 | $29.4B | $115.9B | ||
| Q3 25 | $29.2B | $111.6B | ||
| Q2 25 | $28.3B | $107.4B | ||
| Q1 25 | $28.0B | $104.6B | ||
| Q4 24 | $28.0B | $102.4B | ||
| Q3 24 | $28.3B | $99.8B | ||
| Q2 24 | $26.8B | $100.4B |
负债/权益比BIIBD
| Q1 26 | — | — | ||
| Q4 25 | 0.34× | 1.52× | ||
| Q3 25 | 0.35× | 1.56× | ||
| Q2 25 | 0.36× | 1.48× | ||
| Q1 25 | 0.27× | 1.46× | ||
| Q4 24 | 0.38× | 1.38× | ||
| Q3 24 | 0.28× | 1.35× | ||
| Q2 24 | 0.40× | 1.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $987.0M |
| 自由现金流经营现金流 - 资本支出 | $594.3M | — |
| 自由现金流率自由现金流/营收 | 24.0% | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 1.68× |
| 过去12个月自由现金流最近4个季度 | $2.4B | — |
8季度趋势，按日历期对齐
经营现金流BIIBD
| Q1 26 | — | — | ||
| Q4 25 | $511.9M | $987.0M | ||
| Q3 25 | $1.3B | $1.9B | ||
| Q2 25 | $160.9M | $1.2B | ||
| Q1 25 | $259.3M | $1.2B | ||
| Q4 24 | $760.9M | $641.0M | ||
| Q3 24 | $935.6M | $1.5B | ||
| Q2 24 | $625.8M | $856.0M |
自由现金流BIIBD
| Q1 26 | $594.3M | — | ||
| Q4 25 | $468.0M | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $134.3M | — | ||
| Q1 25 | $222.2M | — | ||
| Q4 24 | $721.6M | — | ||
| Q3 24 | $900.6M | — | ||
| Q2 24 | $592.3M | — |
自由现金流率BIIBD
| Q1 26 | 24.0% | — | ||
| Q4 25 | 20.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 9.1% | — | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 36.5% | — | ||
| Q2 24 | 24.0% | — |
资本支出强度BIIBD
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 1.4% | — |
现金转化率BIIBD
| Q1 26 | — | — | ||
| Q4 25 | — | 1.68× | ||
| Q3 25 | 2.73× | 1.93× | ||
| Q2 25 | 0.25× | 1.64× | ||
| Q1 25 | 1.08× | 1.83× | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 2.41× | 1.61× | ||
| Q2 24 | 1.07× | 1.50× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Product revenue, net | $1.8B | 71% |
| Royalty revenue on sales of OCREVUS | $317.2M | 13% |
| Contract manufacturing, royalty and other revenue | $246.9M | 10% |
| Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO | $94.7M | 4% |
| Alzheimer's collaboration Revenue | $59.5M | 2% |
| Other revenue from anti-CD20 therapeutic programs | $7.2M | 0% |
D
| Dominion Energy Virginia | $3.0B | 72% |
| Nonregulated Electricity Sales | $334.0M | 8% |
| Contracted Energy | $306.0M | 7% |
| Other | $292.0M | 7% |
| Other Nonregulated Revenues | $97.0M | 2% |
| Other Regulated Revenues | $66.0M | 2% |
| Alternative Revenue Programs | $50.0M | 1% |
| Transition Services Agreements | $25.0M | 1% |
| Regulated Gas Transportation And Storage | $10.0M | 0% |
| Related Party | $5.0M | 0% |
